Rhode Island Hospital Rhode Island Hosp. (2) — Providence, Rhode Island

Rhode Island Hospital Rhode Island Hosp. (2) is a clinical research site located in Providence, Rhode Island, United States 02903.

Crixeo Clinical Trials Trust Score: 86/100 (GOOD). This profile has not yet been claimed by the site owner.

Rhode Island Hospital Rhode Island Hosp. (2) has participated in 4 clinical trials.

Therapeutic areas: Tumors With CDK4/6 Pathway Activation, Tumor Pathway Activations Inhibited by Dovitinib, Tumors With Aberrations in ALK or ROS1.

Sponsors: Novartis Pharmaceuticals.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Providence

Browse all research sites in Rhode Island · View every site in Providence

• The Miriam Hospital Clinical Research Site (TMH CRS) CRS
• Brown University Oncology Research Group
• Women & Infants Hospital /ID# 269032
• Rhode Island Hospital /ID# 151538
• VA Providence Healthcare System
• Hasbro Children's Hospital/Rhode Island Hospital
• Brown University Health - Lipid Clinic
• Lifespan Cancer Institute at Rhode Island Hospital
• Department of Orthopaedic Surgery, Rhode Island Hospital
• Vascular Disease Research Center at Rhode Island Hospital
• RI Hospital
• The Weight Control and Diabetes Research Center of The Miriam Hospital & Brown University

Sponsor Feasibility Report

Trust Score: 86/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Rhode Island Hospital Rhode Island Hosp. (2)?

Rhode Island Hospital Rhode Island Hosp. (2) has a Crixeo Trust Score of 86/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Rhode Island Hospital Rhode Island Hosp. (2) conducted?

Rhode Island Hospital Rhode Island Hosp. (2) has 4 clinical trials on record. Their work covers Tumors With CDK4/6 Pathway Activation, Tumor Pathway Activations Inhibited by Dovitinib, Tumors With Aberrations in ALK or ROS1.

Is Rhode Island Hospital Rhode Island Hosp. (2) accredited by Crixeo Clinical Trials?

Rhode Island Hospital Rhode Island Hosp. (2) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Rhode Island Hospital Rhode Island Hosp. (2)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.